Tempus AI beats Q1 expectations, raises 2025 outlook; shares dip 2.3%

Published 06/05/2025, 21:50
Tempus AI beats Q1 expectations, raises 2025 outlook; shares dip 2.3%

Investing.com -- Tempus AI , Inc. (NASDAQ:TEM), a precision medicine technology company, reported better-than-expected first quarter results and raised its full-year revenue guidance, though shares slipped 2.3% following the announcement.

The company posted adjusted earnings per share of -$0.24 for Q1 2025, surpassing analyst estimates of -$0.26. Revenue soared 75.4% YoY to $255.7 million, exceeding the consensus forecast of $248.5 million. Tempus attributed the strong performance to growth across its genomics and data services segments.

"The business is performing well with revenues growing, margins improving, and our costs remaining in check, allowing us to demonstrate significant year-over-year operating leverage," said Eric Lefkofsky, Founder and CEO of Tempus.

Tempus raised its full-year 2025 revenue guidance to $1.25 billion, representing approximately 80% growth YoY. The company also expects to achieve positive adjusted EBITDA of $5 million for the full year, an improvement of about $110 million over 2024.

Quarterly gross profit nearly doubled YoY to $155.2 million, with margins improving in both genomics and data services. The genomics segment contributed $193.8 million in revenue, up 88.9% YoY, while data and services revenue grew 43.2% to $61.9 million.

Tempus recently announced strategic collaborations with AstraZeneca (NASDAQ:AZN) and Pathos to develop a multimodal foundation model in oncology, which is expected to generate an additional $200 million in data licensing and model development fees over the next three years.

Despite the positive results and outlook, Tempus shares edged down 2.3% in after-hours trading, possibly due to high investor expectations.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.